ERBB2 and breast carcinoma: A total of 250 heavily pretreated patients with HER2-positive breast cancer, HER2+ gastric/GEJ carcinoma, low-HER2 BC, HER2-expressing/mutated NSCLC, or other HER2-expressing/mutated solid tumors were enrolled.